Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Maria Dziekan

Physician Assistant Niagara Falls, NY Physician Assistant

NPI 1891311239 CMS profile 11068012

4519 Military Rd, Niagara Falls, NY 14305

Open in the dashboard

General payments

$5,614

282 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maria Dziekan of Niagara Falls, NY is reported in the CMS Open Payments database as having received $5,614 across 282 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,247 104
2024 General $1,768 93
2023 General $1,299 59
2022 General $187 11
2021 General $113 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maria Dziekan
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Maria Dziekan were reported at $2,247. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Maria Dziekan Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $113 $132 $37–$438 $132
2022 $187 $155 $48–$522 $149
2023 $1,299 $167 $52–$557 $160
2024 $1,768 $178 $55–$600 $164
2025 $2,247 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,347 54 payments
  2. Regeneron Healthcare Solutions, Inc. $1,035 67 payments
  3. Genzyme Corporation $1,013 46 payments
  4. GlaxoSmithKline, LLC. $993 56 payments
  5. Amgen Inc. $207 11 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $180 9 payments
  7. BioCryst US Sales Co., LLC $134 6 payments
  8. ARS Pharmaceuticals Operations, Inc. $122 5 payments
  9. OptiNose US, Inc. $86 4 payments
  10. Novartis Pharmaceuticals Corporation $85 4 payments
  11. Other $412 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,614 282 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,318 62 payments
  2. AIRSUPRA $640 24 payments
  3. DUPIXENT Immunology And Inflammation $527 26 payments
  4. DUPIXENT Inflammation And Immunology $508 41 payments
  5. FASENRA $501 21 payments
  6. NUCALA $464 23 payments
  7. TRELEGY ELLIPTA $361 28 payments
  8. TEZSPIRE Respiratory $215 5 payments
  9. TEZSPIRE Inflammation $186 10 payments
  10. AREXVY $141 2 payments
  11. Other $1,379 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

545

Median for Physician Assistant: 241

Drug cost

$65,665

Median for Physician Assistant: $4,110

Branded share of claims

21.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $27,390
Epinephrine Generic 42 $11,589
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 14 $11,214
Symbicort Budesonide/Formoterol Fumarate Brand 20 $7,271
Qvar Redihaler Beclomethasone Dipropionate Brand 11 $2,305
Albuterol Sulfate Hfa Albuterol Sulfate Brand 47 $1,498
Azelastine Hcl Generic 47 $1,103
Fluticasone Propionate Generic 63 $1,085
Montelukast Sodium Generic 104 $897
Famotidine Generic 85 $618

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$13,814

Medicare's payments for the services billed

Medicare patients

75

Average age 66

Services billed

1,246

58 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 47%
Diabetes 27%
Depression 25%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $518
  • Regeneron Healthcare Solutions, Inc. $337
$855 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $276
$276 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $170
$170 — —
NUCALA
  • GlaxoSmithKline, LLC. $134
$134 — —
Orladeyo
  • BioCryst US Sales Co., LLC $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record